New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 19, 2013
08:10 EDTACST, NEPTAcasti Pharma presents preliminary data on NKPL66
Acasti Pharma (ACST), a Neptune Technologies & Bioressources (NEPT) subsidiary, announces encouraging preliminary clinical data of its "Randomized, Open-Label, Dose-Ranging, Multi-Center Trial to assess the Safety and efficacy of NKPL66 in the treatment of mild-to-high hypertriglyceridemia". In the course of planning the strategy of its phase III clinical development with CaPre, Acasti examined triglycerides data from its Open-label clinical trial.Data from 157 patients who have completed four weeks of treatment with 0.5, 1, 2 or 4 grams of CaPre per day were assessed and CaPre achieved a clinically important and statistically significant triglyceride reduction of up to 23% as compared to standard of care, after only a 4-week treatment. Moreover, a noteworthy trend indicating a dose-response relationship versus standard of care as well as clinically and statistically significant effects of doubling the doses of CaPre were observed. To date, the results of this preliminary analysis suggest that CaPre is safe and effective for the treatment of patients with triglyceride levels ranging from 200 to 500 mg/dL.
News For ACST;NEPT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 25, 2015
07:37 EDTACSTAcasti Pharma granted patent in China
Subscribe for More Information
March 23, 2015
19:10 EDTACST, NEPTNeptune, Acasti announce USPTO decision that triggers royalty payments
Neptune Technologies & Bioressources (NEPT) and Acasti Pharma (ACST) announced that the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office, or USPTO, issued a favorable decision, confirming the validity of certain claims in Neptune's '351 patent and triggering royalty payments to Neptune. "This is a significant milestone that triggers the payment of ongoing royalties to Neptune by Aker and Enzymotec, based on their sales of licensed krill oil products in the US," said Neptuine CEO Jim Hamilton.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use